Patients who have chronic kidney disease and pulmonary hypertension are at a greater risk for a variety of adverse outcomes, according to new research.
Tag: pulmonary hypertension
The use of and outcomes with PH drug ambrisentan in clinical practice are different to those in clinical trials, reflecting different patient characteristics in the “real world”, say researchers.Read More
After a year of being treated with a novel drug, Riociguat, patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH), and those with persistent or recurrent pulmonary hypertension after an operation for the disease, showed sustained improvement.Read More
The drug, ricoiguat, could prove effective as a treatment option for patients with PAH.Read More